Publication details
Novinky v léčbě hepatitidy C
| Title in English | News in the treatment of hepatitis C |
|---|---|
| Authors | |
| Year of publication | 2015 |
| Type | Article in Periodical |
| Magazine / Source | Interní medicína pro praxi |
| MU Faculty or unit | |
| Citation | |
| Field | Epidemiology, infectious diseases and clinical immunology |
| Keywords | hepatitis C; pegylated interferon; ribavirin; boceprevir; telaprevir; sofosbuvir; simeprevir; daclatasvir; ledipasvir |
| Description | Treatment of chronic hepatitis C is undergoing extraordinary changes in the past 4 years. Direct-Acting Antivirals (DAA) are gradually introducing into routine clinical practice either in combination with pegylated interferon and ribavirin, or in interferon-free or even ribavirin-free regimes. Sofosbuvir, simeprevir, and fixed combination of sofosbuvir and ledipasvir have been already approved in the European Union and United States. Daclatasvir has been additionally approved in the European Union. The advantages of DAA are high potency and minimum of adverse events. |